Cellular Biomedicine Group Inc. (CBMG)’s Financial Results Comparing With VistaGen Therapeutics Inc. (NASDAQ:VTGN)

This is therefore a comparing of the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation in Cellular Biomedicine Group Inc. (NASDAQ:CBMG) and VistaGen Therapeutics Inc. (NASDAQ:VTGN). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellular Biomedicine Group Inc. N/A 1383.48 38.95M -2.20 0.00
VistaGen Therapeutics Inc. N/A 0.00 24.06M -0.93 0.00

Table 1 highlights Cellular Biomedicine Group Inc. and VistaGen Therapeutics Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Cellular Biomedicine Group Inc. 0.00% -46.2% -43.2%
VistaGen Therapeutics Inc. 0.00% -608.9% -267.7%

Volatility & Risk

A 3.18 beta means Cellular Biomedicine Group Inc.’s volatility is 218.00% more than S&P 500’s volatility. In other hand, VistaGen Therapeutics Inc. has beta of -0.47 which is 147.00% less volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of Cellular Biomedicine Group Inc. are 8.9 and 8.9 respectively. Its competitor VistaGen Therapeutics Inc.’s Current Ratio is 3.6 and its Quick Ratio is 3.6. Cellular Biomedicine Group Inc. can pay off short and long-term obligations better than VistaGen Therapeutics Inc.

Analyst Recommendations

Cellular Biomedicine Group Inc. and VistaGen Therapeutics Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cellular Biomedicine Group Inc. 0 0 2 3.00
VistaGen Therapeutics Inc. 0 0 0 0.00

Cellular Biomedicine Group Inc. has a 86.37% upside potential and a consensus target price of $32.

Institutional and Insider Ownership

Roughly 19.3% of Cellular Biomedicine Group Inc. shares are owned by institutional investors while 18% of VistaGen Therapeutics Inc. are owned by institutional investors. 39.63% are Cellular Biomedicine Group Inc.’s share owned by insiders. Comparatively, VistaGen Therapeutics Inc. has 0.1% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cellular Biomedicine Group Inc. 4.14% 6.13% -7.28% -5.94% 11.6% 6.8%
VistaGen Therapeutics Inc. -16.18% -30.91% -33.33% -23.49% -3.39% -24%

For the past year Cellular Biomedicine Group Inc. had bullish trend while VistaGen Therapeutics Inc. had bearish trend.

Summary

Cellular Biomedicine Group Inc. beats on 6 of the 8 factors VistaGen Therapeutics Inc.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy. The company has a strategic research collaboration with GE Healthcare Life Sciences China to co-develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing. Cellular Biomedicine Group Inc. was incorporated in 2001 and is headquartered in Cupertino, California.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.